arrow
D

Daniel Jenkin

University of Oxford
H指数:24
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial

乌干达健康成人中ChAdOx1 RVF疫苗预防裂谷发热的安全性、耐受性和免疫原性: 一项单中心、单盲、随机、安慰剂对照、剂量递增、1期试验

2025-11-110
OAAI
Safety and immunogenicity of a bivalent Ebola virus and Sudan virus ChAdOx1 vectored vaccine in adults in the UK: an open-label, non-randomised, first-in-human, phase 1 clinical trial

英国成人中二价埃博拉病毒和苏丹病毒ChAdOx1载体疫苗的安全性及免疫原性:一项开放标签、非随机、首次人体、1期临床试验

2025-02-010
OAAI
Safety of a controlled human infection model of tuberculosis with aerosolised, live-attenuated Mycobacterium bovis BCG versus intradermal BCG in BCG-naive adults in the UK : a dose-escalation, randomised, controlled, phase 1 trial
2024-08-018
OAAI
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
2023-08-0110
OAAI
Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials

两剂ChAdOx1 nCov-19 (AZD1222) 后免疫反应的持续性: 两项随机对照试验的1年随访

2023-02-028
OAAI
Tolerability and immunogenicity of an intranasally- administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
2022-11-0182
OAAI
An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
2022-07-019
OAAI
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
2022-04-0834
OA
Deep Immune Phenotyping and Single-Cell Transcriptomics Allow Identification of Circulating TRM-Like Cells Which Correlate With Liver-Stage Immunity and Vaccine-Induced Protection From Malaria
2022-02-0713
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

ChAdOx1 nCoV-19 (AZD1222) 疫苗对巴西流行的SARS-CoV-2谱系的功效

2021-10-0638
OAAI
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
LANCET
IF88.5
2021-09-01175
OAAI
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
2021-08-01185
OAAI
A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial
2021-07-3035
OAAI
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial (vol 27, pg 270, 2021)
2021-05-215
OAAI
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses (vol 27, pg 279, 2021)
2021-05-066
OAAI
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

ChAdOx1 nCoV-19 (AZD1222) 疫苗对SARS-CoV-2相关变异202012/01 (B.1.1.7) 的疗效: 一项随机对照试验的探索性分析

LANCET
IF88.5
2021-04-01410
OAAI
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
LANCET
IF88.5
2021-03-01841
OAAI
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

ChAdOx1 nCoV-19疫苗 (AZD1222) 抗SARS-CoV-2的安全性和有效性: 对巴西、南非和英国的四项随机对照试验的中期分析

LANCET
IF88.5
2021-01-013.2K
OAAI